Telavancin
Also known as: TD-6424, Telavancin dihydrochloride, televancin, TLV, Vancocin, Vibativ
Source Telavancin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Telavancin is a lipoglycopeptide antibiotic administered intravenously and approved for the treatment of complicated skin and skin‑structure infections, as well as hospital‑acquired and ventilator‑associated bacterial pneumonia caused by Staphylococcus aureus, including methicillin‑resistant strains (MRSA). It is prescribed when other agents may be ineffective or unsuitable, offering a bactericidal option for serious Gram‑positive infections.
Mechanism of Action
Telavancin, like other glycopeptide antibiotics, binds to the D‑Ala‑D‑Ala termini of peptidoglycan precursors, blocking the transglycosylation step of cell‑wall synthesis. This interference compromises the structural integrity of the bacterial cell wall, leading to cell lysis and death of Gram‑positive organisms such as Staphylococcus aureus. The drug’s lipophilic side chain enhances its binding affinity and may also disrupt bacterial membrane function, contributing to its bactericidal activity.
What the Research Shows
A 2016 systematic review and meta‑analysis of five randomized controlled trials (3,790 participants) found telavancin’s clinical cure rates to be comparable to other antibiotics for S. aureus infections, with no significant difference in pathogen eradication. While overall mortality and serious adverse events were similar, telavancin was associated with higher rates of adverse‑event‑related withdrawal (OR 1.47) and more frequent gastrointestinal, nervous, and urogenital side effects. Laboratory abnormalities, notably serum creatinine elevation (OR 2.25) and hypokalemia (OR 1.74), were also more common, indicating potential nephrotoxicity. A 2024 network meta‑analysis of MRSA infections reported that telavancin achieved superior microbiological success compared with vancomycin (RR 0.74). Additionally, a 2019 review highlighted precautionary statements for reduced efficacy in patients with baseline creatinine clearance of 30‑50 mL/min, suggesting that dose reductions in acute kidney injury may compromise outcomes.
Reported Benefits
Telavancin provides a potent option against MRSA and other resistant Gram‑positive pathogens, with efficacy comparable to standard agents for complicated skin infections and hospital‑acquired pneumonia. Evidence from network meta‑analysis suggests it may achieve better microbiological eradication than vancomycin, making it a valuable alternative when vancomycin resistance or treatment failure is a concern.
Limitations of the Evidence
Clinical cure rates are not superior to comparator antibiotics, and telavancin carries a higher incidence of adverse events, especially gastrointestinal, neurological, and urogenital symptoms. Renal toxicity, manifested by increased serum creatinine and hypokalemia, limits its use in patients with impaired kidney function. Evidence is primarily derived from meta‑analyses of existing trials; further high‑quality, head‑to‑head studies are needed to clarify its relative advantages.
Safety Considerations
Patients receiving telavancin experience more total adverse events than those on other antibiotics, with notable increases in digestive, nervous, and urogenital complaints. Laboratory monitoring often reveals rises in serum creatinine and reductions in potassium, reflecting potential nephrotoxicity. Higher rates of treatment discontinuation due to adverse events have been reported. Caution is advised in individuals with baseline renal dysfunction, and renal function should be closely monitored throughout therapy.
How It Is Administered
Telavancin is supplied for intravenous infusion only. Dosing is typically weight‑based and adjusted according to renal function, with special attention to patients whose creatinine clearance falls between 30 and 50 mL/min. The drug is administered in a hospital or clinical setting under professional supervision.
Routes of Administration
Goals & Uses
- Treatment of ventilator-associated bacterial pneumonia (VABP)Antibacterial / Infection TreatmentHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Treatment of bacteremia due to Gram-positive organismsAntibacterial / Infection TreatmentModerate
- Treat hospital‑acquired bacterial pneumoniaInfectionHigh
- Treatment of complicated skin and skin structure infections (cSSSI)Antibacterial / Infection TreatmentHigh
- Target methicillin‑resistant Staphylococcus aureus (MRSA)AntimicrobialHigh
- Treat complicated skin and skin structure infectionsInfectionHigh
- Treatment of hospital-acquired bacterial pneumonia (HABP)Antibacterial / Infection TreatmentHigh
Contraindications
- Use with QTc-prolonging agents in patients with known QT prolongationCardiacModerate
- Severe renal impairment (CrCl <30 mL/min) without dose adjustmentRenalModerate
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to telavancin or any componentAllergyHigh
- Severe renal impairment (CrCl <10 mL/min)RenalHigh
- Hypersensitivity to telavancin, vancomycin, or other glycopeptidesAllergyHigh
Adverse Effects
- QT interval prolongationCardiacRare
- ThrombocytopeniaHematologicUncommonLow platelet count
- Interference with coagulation tests (PT, INR, aPTT)LaboratoryCommon
- QTc prolongationCardiacUncommon
- Taste disturbance (dysgeusia)SensoryCommon
- Foamy urineRenal / UrinaryCommon
- Infusion‑related reactionsGeneralCommon
- Nausea and vomitingGastrointestinalCommon
- Nephrotoxicity (renal impairment)RenalCommon
- NephrotoxicityRenalCommon
- Infusion-related reactions (Red Man Syndrome)Infusion ReactionCommon
Drug Interactions
- AminoglycosidesHigh
- Nephrotoxic agents (aminoglycosides, NSAIDs, amphotericin B)High
- WarfarinLow
- Other QT‑prolonging drugs (e.g., macrolides, fluoroquinolones)Moderate
- QTc-prolonging drugs (e.g., haloperidol, amiodarone, fluoroquinolones)Moderate
- Unfractionated HeparinLow
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patients (<18 years)AgeAbsolute
- Pediatric patientsAgeRelative
- Women of childbearing potential without contraceptionReproductiveRelative
- Patients with known QT prolongation or congenital long QT syndromeCardiacRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaEMA approval 2010
- United StatesApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaApproved 2009
- United KingdomApprovedApproved: Complicated skin and skin structure infections, Hospital‑acquired bacterial pneumoniaApproved under same indications as EU
FDA approved in 2009 (Vancocin) for cSSSI and HABP/VABP; EMA approval 2010; not approved for pediatric patients under 18.
Evidence & Sources
- Journal ArticleModerateChuan J, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateYim G, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateCrass RL, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateLiu Q, et al.2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What infections is telavancin approved to treat?
Telavancin is approved for intravenous treatment of complicated skin and skin‑structure infections and for hospital‑acquired or ventilator‑associated bacterial pneumonia caused by Staphylococcus aureus, including methicillin‑resistant strains.
How does telavancin differ from vancomycin?
Both target the bacterial cell wall, but telavancin’s lipophilic side chain enhances binding and may disrupt membrane function. Some analyses suggest telavancin achieves better microbiological eradication of MRSA, though overall clinical cure rates are similar.
What are the main safety concerns with telavancin?
The drug is associated with higher rates of gastrointestinal, nervous, and urogenital side effects, as well as laboratory abnormalities such as increased serum creatinine and hypokalemia, indicating a risk of nephrotoxicity. Monitoring renal function is essential.
Should the dose be reduced in patients with kidney problems?
Regulatory guidance recommends dose adjustment for patients with a creatinine clearance of 30‑50 mL/min, but some experts caution that premature reduction may diminish efficacy, especially in acute kidney injury. Individual assessment and careful monitoring are advised.
Is telavancin given orally or by injection?
Telavancin is only available as an intravenous formulation and must be administered by infusion in a clinical setting.
What is Telavancin?
Telavancin is a lipoglycopeptide antibiotic administered intravenously and approved for the treatment of complicated skin and skin‑structure infections, as well as hospital‑acquired and ventilator‑associated bacterial pneumonia caused by Staphylococcus aureus, including methicillin‑resistant strains (MRSA). It is prescribed when other agents may be ineffective or unsuitable, offering a bactericidal option for serious Gram‑positive infections.
What is Telavancin used for?
Telavancin is educationally associated with: Treatment of ventilator-associated bacterial pneumonia (VABP), Treatment of MRSA infections, Treatment of bacteremia due to Gram-positive organisms, Treat hospital‑acquired bacterial pneumonia, Treatment of complicated skin and skin structure infections (cSSSI), Target methicillin‑resistant Staphylococcus aureus (MRSA), Treat complicated skin and skin structure infections, Treatment of hospital-acquired bacterial pneumonia (HABP). Educational only — not medical advice.
How is Telavancin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Telavancin?
Reported adverse effects include: QT interval prolongation, Thrombocytopenia, Interference with coagulation tests (PT, INR, aPTT), QTc prolongation, Taste disturbance (dysgeusia), Foamy urine, Infusion‑related reactions, Nausea and vomiting, Nephrotoxicity (renal impairment), Nephrotoxicity, Infusion-related reactions (Red Man Syndrome). This list is not exhaustive — consult a qualified clinician.
Who should avoid Telavancin?
Recorded contraindications: Use with QTc-prolonging agents in patients with known QT prolongation, Severe renal impairment (CrCl <30 mL/min) without dose adjustment, Pregnancy, Hypersensitivity to telavancin or any component, Severe renal impairment (CrCl <10 mL/min), Hypersensitivity to telavancin, vancomycin, or other glycopeptides. Consult a qualified clinician before use.